Patents by Inventor Kung-Pern Wang

Kung-Pern Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES
    Publication number: 20250090875
    Abstract: The present disclosure provides, inter alia, antibody drug conjugates that are useful in treating various diseases such as cancer. The antibody drug conjugates can be configured to elicit tumor site-specific responses, including tumor microenvironment immunostimulation, while limiting off-target and systemic effects. In certain embodiments disclosed herein, the antibody drug conjugates are configured to release payloads following internalization by immune, cancer, or tumor associated cells.
    Type: Application
    Filed: July 31, 2023
    Publication date: March 20, 2025
    Inventors: Kung-Pern WANG, Alyson SMITH, Christopher Scott NEUMANN, Shyra J. GARDAI, David FERGUSON
  • QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES
    Publication number: 20240293554
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: January 16, 2024
    Publication date: September 5, 2024
    Inventors: Christopher Scott NEUMANN, Kathleen OLIVAS, Robert LYON, Kung-Pern WANG
  • IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES
    Publication number: 20240165251
    Abstract: The present disclosure provides, inter alia, antibody drug conjugates that are useful in treating various diseases such as cancer. The antibody drug conjugates can be configured to elicit tumor site-specific responses, including tumor microenvironment immunostimulation, while limiting off-target and systemic effects. In certain embodiments disclosed herein, the antibody drug conjugates are configured to release payloads following internalization by immune, cancer, or tumor associated cells.
    Type: Application
    Filed: July 31, 2023
    Publication date: May 23, 2024
    Inventors: Kung-Pern WANG, Alyson SMITH, Christopher Scott NEUMANN, Shyra J. GARDAI, David FERGUSON
  • Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
    Patent number: 11931414
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 19, 2024
    Assignee: Seagen Inc.
    Inventors: Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang
  • ADCS WITH THIOL MULTIPLEX LINKERS
    Publication number: 20220040320
    Abstract: The present disclosure provides, inter alia, thiol multiplexed Antibody Drug Conjugates (TM-ADCs) and Multiplex Linking Assemblies (MLAs) that comprise multiple Drug Moieties in a single linking assembly.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 10, 2022
    Inventors: Scott Jeffrey, Kung-Pern Wang
  • ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME
    Publication number: 20210085796
    Abstract: The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune the properties of the compound within the body such that the compound more selectively distributes to tumors and is, or becomes active in the cytosol.
    Type: Application
    Filed: July 27, 2018
    Publication date: March 25, 2021
    Inventors: John DEACON, Kung-Pern WANG, Donald ENGELMAN, Denton HOYER, Apiwat WANGWEERAWONG, William HUNGERFORD, Venkatareddy SABBASANI, David SPIEGEL
  • Prodrugs Activated by Reduction in the Cytosol
    Publication number: 20200384002
    Abstract: The present invention provides prodrug modifications for chemotherapeutic drugs that allow activation in the cytosol.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 10, 2020
    Inventors: John Deacon, Kung-Pern Wang, Venkatareddy Sabbasani
  • QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES
    Publication number: 20200197524
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang